Home>Topics>Stocks>Exact Sciences

Exact Sciences EXAS

  1. All
  2. Commentary
  3. Headlines
    1. From Barron’s, March 31, 2014 (Part 2)

      Commentary

      Sat, 29 Mar 2014

      ancillary-benefit suppliers MET, UNM ; PBMs CVS, ESRX ; managed-care providers AET, UNH, CI ; pg 17]; Exact Sciences [ EXAS ; impending FDA approval of its colon cancer screening test; pg 19]; REITs with DC office exposure [ BDN

    2. Connecting the DOTs: The Role of North America’s ‘Emerging Markets’ in Achieving Energy Independence

      Headlines

      Fri, 18 Oct 2013

      Dakota and Western Canada should grow 10% per year over the next 3 years. In our opinion, North D akota, O klahoma and T exas are critical states from a production, pipeline route, storage and end-market consumption perspective. We believe these

    3. From Barron’s, October 8, 2012 (Part 2)

      Commentary

      Sat, 6 Oct 2012

      favorable trials of muscular dystrophy drug; pg 18); Viacom ( VIA/VIAB ; pg 21); Brink’s ( BCO ; pg 22); Exact Sciences ( EXAS ; DNA-based Cologuard test trials appear promising; pg 25); Walgreen ( WAG ; 5-yr valuation low; pg 34

    4. Dropping Coverage of Exact Sciences

      Commentary

      Tue, 1 May 2007

      We are dropping coverage of Exact Sciences EXAS to focus our resources elsewhere.

    5. Exact Reports 3Q Results

      Commentary

      Tue, 24 Oct 2006

      Exact Sciences EXAS reported third-quarter results that met our expectations, so we are sticking to our $2 fair value estimate. However, delays

    6. Exact Sciences Makes Slow Progress

      Commentary

      Wed, 26 Apr 2006

      There were no major surprises in Exact Sciences ' EXAS first-quarter results, and we're leaving our fair value estimate at $2.30 per share. The company is making slow progress

    7. FDA Will Review EXACT Test

      Commentary

      Mon, 30 Jan 2006

      The U.S. Food and Drug Administration recently announced that EXACT Sciences ' EXAS PreGen-Plus colorectal cancer test is subject to FDA regulation and will require a review as a medical device. The FDA's position

    8. Exact Sciences Under Review

      Commentary

      Tue, 10 Jan 2006

      We're putting Exact Sciences EXAS under review while we transition coverage to a new analyst. We're also looking more closely into the results of a recent study

    9. Reduced Fair Value for EXAS

      Commentary

      Wed, 3 Aug 2005

      more time passes we think it is less likely that Exact Sciences ' EXAS PreGen-Plus will be included in screening guidelines ..... will reimburse the test. The clock is ticking, and Exact Sciences may get dangerously close to running out of cash

    10. Exact Sciences under Review

      Commentary

      Fri, 29 Jul 2005

      We are placing Exact Sciences EXAS under review as we digest continued low volume levels for PreGen ..... obtains wide reimbursement, but we question whether we should give Exact Sciences too much credit for those two potential events. We will probably

    « Prev12Next »
    Content Partners